Medicamen Organics Limited (MOL) has announced a strategic collaboration with Medi Hub Organic Limited (MHOL), a newly incorporated Nepal-based entity, to establish a state-of-the-art pharmaceutical manufacturing facility. The initiative aims to bolster regional healthcare capabilities and enhance self-sufficiency in Nepal’s pharmaceutical sector.
Key Highlights of the Collaboration:
- Investment: MOL will invest ₹9 crore (NPR 14.4 crore) in MHOL, acquiring a 30% stake.
- Facility Standards: The manufacturing unit will comply with CGMP norms and target European quality standards for global competitiveness.
- Focus Areas: The partnership will produce a wide range of pharmaceutical, herbal, nutraceutical, and medical products.
- Technology Transfer: The collaboration will emphasize innovation, product enhancement, and technology sharing to serve both domestic and international markets.
Strategic Objectives:
This partnership strengthens Medicamen Organics’ footprint in South Asia and EU markets. The facility will leverage Medicamen’s production expertise, ensuring high-quality product availability while contributing to Nepal’s healthcare ecosystem.
Comments from Leadership:
Bal Kishan Gupta, Managing Director of Medicamen Organics, remarked, “This collaboration reflects our commitment to addressing healthcare needs through strategic regional expansions and leveraging synergies for innovation.”
About the Companies:
- Medicamen Organics: A leading pharmaceutical manufacturer with WHO GMP-certified facilities in India. It operates in government tenders, B2B contracts, and exports to African, CIS, and Southeast Asian countries.
- Medi Hub Organic: A Nepal-based entity focusing on manufacturing pharmaceutical and herbal products, with aspirations to become a significant player in South Asia.
